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Abstract
Background: Breast cancer is the fourth leading cause of death and disability in the Eastern Mediterranean Region (EMR); 
although the incidence is lower than in the developed regions, there has been an increasing trend in recent decades.
Aims: Our aim was to calculate the pooled survival rate of patients with breast cancer in the EMR. 
Methods: We searched electronic databases from 1946 to 19 January 2018, without language restrictions. We used a ran-
dom effect model to estimate pooled 1-, 3-, 5- and 10-year survival rates for patients with breast cancer. Chi-squared and I2 
index were used to assess between-study heterogeneity. Subgroup analysis and meta-regression were used to investigate 
the potential source of heterogeneity. 
Results: We found 80 articles eligible for inclusion in our review. The pooled 1-, 3-, 5- and 10-year survival rates in wom-
en with breast cancer in the EMR were 0.95, 0.80, 0.71, and 0.56, respectively. The I2 index indicated considerable be-
tween-study heterogeneity (all I2 > 50%). The 5-year survival rate in the male subgroup was 0.63. The 5-year survival rate 
of women with breast cancer in age groups ≤ 39, 40–64, and 65+ years were 0.74, 0.76 and 0.58, respectively. There was a 
statistically significant association between the Human Development Index (β = 9, P = 0.01) and decade of study (β = 8.2, 
P = 0.04) and 5-year survival rate. 
Conclusions: The survival rate of women with breast cancer in those countries in the EMR which have better health care 
systems improved in the past decade; women aged 40–64 years had the best survival rate.
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Introduction
Breast cancer is among the 4 most common cancers 
in the world (1). It is the leading cause of death among 
women in developed countries and the second common-
est cause of death in developing countries (2,3). In 2015, 
among women, an estimated 321 840 new cases of inva-
sive breast cancer were projected (4). In the WHO Eastern 
Mediterranean Region (EMR), breast cancer is the fourth 
leading cause of death and disability (1,3,5) and the num-
ber one cancer in 16 of the 22 countries in the Region (6). 
The age-standardized incidence of breast cancer in this 
Region is 12–50 per 100 000 in women, with the lowest 
incidence in the Islamic Republic of Iran and Pakistan (3). 
Although the incidence in this Region is lower than in the 
developed regions, there has been an increasing trend in 
recent decades (10,11). 
The EMR comprises 22 countries with varied ethnicity 
and cultures (7). The women in this Region generally 
have poor knowledge about screening methods for breast 
cancer (6). In Bahrain, Egypt, the Islamic Republic of Iran, 
Jordan, Kuwait, Lebanon, Oman, Saudi Arabia and Tunisia, 
breast cancer is usually diagnosed in women under age 50 
years, i.e. younger than in other parts of the world (6). 
An important factor that affects survival is the disease 
stage at diagnosis, ranging from ≥ 80% in North America, 
Sweden and Japan to around 60% in middle-income 
countries and < 40% in low-income countries (7). In the 
EMR, patients with breast cancer are usually diagnosed 
for the first time at stages 2 and 3 (3,6). The difference in 
survival between developed and developing countries 
may be due to delays in diagnosis. 
The aim of this study is to determine survival of 
patients with breast cancer by age, stage of disease and 




The Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines was used to carry out 
and report this systematic review and meta-analysis (8).
Study selection
We used the following inclusion and exclusion crite-
ria to select relevant articles in this meta-analysis. All 
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observational cohort studies that reported the survival 
rate of women with primary invasive breast cancer in 
different study populations in the EMR were included 
with no restriction for language, age, ethnicity or reli-
gion. We excluded articles that reported the survival 
rate after relapse. Letters to the editor, review articles 
and meeting abstracts were also excluded. Where we 
found several publications from the same study popu-
lation, we choose the most recent one to include in our 
study. To select the relevant articles from the search re-
sults, 2 reviewers (KM and MK) independently screened 
the studies by title, abstract and full text; in the case of 
disagreement between the 2 reviewers, they entered 
into discussion and if required a 3rd investigator be-
came involved to resolve the question. 
Search strategy
A systematic search was carried out by 2 reviewers (KM 
and MK) independently in several electronic databases 
such as Medline/PubMed, Web of Science, Scopus, and 
Google Scholar covering material published from 1946 to 
19 January 2018. The search strategy was made using the 
MeSH subject headings and free text words like (“breast 
neoplasms” [MeSH] or “breast cancer” or “breast carci-
noma” or “breast tumour” or “breast malignant”) AND 
(“survival” or “survival analysis” or “survival rate” or “life 
table” or “Kaplan Meier “ or “proportional hazard mod-
el” or “hazard ratio” or “Cox model” or “ Cox regression”) 
AND (“cohort” or “prospective” or “retrospective” or “fol-
low-up” or “longitude”). To identify additional relevant 
studies, we reviewed the reference lists of all included 
studies. To manage and screen eligible searched studies, 
we used EndNote X7 citation manager. 
Quality assessment
To assess the quality of each eligible study and risk of 
bias we used the Strengthening the Reporting of Ob-
servational Studies in Epidemiology (STROBE) checklist 
(9). We used several items from this checklist: define 
the source of participant selection, explain the eligibili-
ty criteria, explain about follow-up and how to address 
the missing data, clearly define how to measure the out-
come and explain about the size of the study. The stud-
ies were classified into 3 groups based on this checklist. 
If the studies attained more than 80% of the total score, 
they were classified as high quality, 60–79% of total score 
as intermediate quality and 30–59% of total score as low 
quality. Two authors (KM and MK) independently in-
vestigated the quality of each study. The agreements be-
tween reviewers were assessed by weighted Kappa (86%). 
Data extraction
For each eligible study, the variables were extracted on 
a prespecified sheet in Microsoft Excel 2010 as follows: 
first author name, year of publication, period of study, 
country of origin, source of data, study design, median 
follow-up time, sample size, mean age, gender frequen-
cy, type of survival, 1-, 3-, 5- and 10-year survival rates 
and 95% confidence interval (CI). Data extraction was 
performed independently by 2 reviewers (KM and MK). 
Disagreement was resolved by discussion between the 
2 reviewers and if required, a senior investigator solved 
the discrepancies. 
Statistical analysis
We investigated statistical heterogeneity using the Q 
test at the 5% significance level (P < 0.05) and I2 index. Ac-
cording to the significant between-study heterogeneity 
(P < 0.05), random effect models was used. Because some 
studies did not report the standard error and 95% confi-
dence interval (CI), we also used binomial distribution to 
estimate the variance and 95% CIl of all included studies. 
To estimate the pooled survival rate we used metan 
and metaprop commands. The metaprop command 
was specific to binomial data and for proportions near 
boundaries (in this instance, 100% at 1-year survival 
or 0% at stage IV), which allows computation of exact 
binomial and score test-based CIs by allowing Freeman–
Tukey double arcsine transformation to stabilize the 
variances (10). 
To investigate the potential source of heterogeneity 
we used subgroup analyses based on sex, age and stage 
at diagnosis, ethnicity, Human Development Index 
(HDI) and decade of study. We also conducted subgroup 
analysis based on the level of development, income and 
health outcome, so all 22 countries were categorized into 3 
subgroups. Group 1 includes countries that are developed 
in the past decade, Group 2 includes middle-income 
countries and Group 3 includes countries less developed 
than the others in the Region, e.g. Afghanistan (11,12).
Meta-regression was used based on decade of study, 
HDI, ethnicity, and sample size to find the source of 
heterogeneity. Publication bias was not assessed, because 
the probability of survival rate as a proportion is always 
a positive number and if we see asymmetry in a funnel 
plot, it is not due to publication bias. 
We used EndNote X7 to manage the records and 
review the results of the systematic search and Microsoft 
Excel 2010 to prepare the data extraction sheet. We used 
Stata 11 to perform statistical analysis.
Results
Study characteristics
The initial search identified 1292 articles up to 19th Janu-
ary 2018. After removing duplicates and screening by ti-
tle, abstract and full text, 80 eligible articles remained in 
our systematic review and meta-analysis. A flow diagram 
of selection process according to the PRISMA flowchart 
is shown in Figure 1. 
The characteristics of these 80 studies are summarized 
in Table 1. These articles come from 12 countries in the 
EMR. Half of the studies were conducted in the Islamic 
Republic of Iran (n = 40); 12 articles were exclusively 
conducted on men and 68 on women. Also, 6 studies 
were exclusively conducted on women under 39 years. 
The total sample size from the 80 studies was 42 328, of 
whom 41 603 (98.2%) were female.
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Pooled survival rate
The pooled 1-, 3-, 5- and 10-year survival rate of women 
with breast cancer in the EMR were 0.95 (95% CI: 0.93–
0.96), 0.80 (95% CI: 0.76–0.84), 0.71 (95% CI: 0.68–0.73) and 
0.56 (95% CI: 0.48–0.63), respectively. We saw consider-
able heterogeneity in 1-year (P < 0.001, I2 = 92.83), 3-year 
(P < 0.001, I2 = 96.38), 5-year (P < 0.001, I2 = 92.24) and 10-
year (P < 0.001, I2 = 97.33) survival rates among women 
with breast cancer. 
Subgroup analysis
The results of the subgroup analyses are shown in Table 2. 
The pooled 5-year survival rate in women was 0.71 (95% 
CI: 0.68–0.73) and in men was 0.63 (95% CI: 0.59–0.67). In 
the age subgroups, the 5-year survival rates for women 
with breast cancer aged < 39, 40–64, and 65+ years were 
0.74 (95% CI: 0.68–0.80), 0.76 (95% CI: 0.66–0.85) and 0.58 
(95% CI: 0.46–0.69) respectively. 
Meta-regression
To determine any potential source of bias, we covered the 
variables sample size, HDI, decade of study and ethnicity 
as independent variables and survival rate as a depend-
ent variable in meta-regression. In the univariable model, 
there was a statistically significant association between 
HDI (β = 9.0, P = 0.012) and decade of study (β = 8.2, P = 
0.048) and 5-year survival rate. The 5-year survival rate 
increased with the decade of study (Table 3). 
Discussion 
The aim of this study was to estimate the survival rate 
of women with breast cancer in the EMR. From the me-
ta-analysis, the 1-, 3-, 5- and 10-year survival rates were 
0.95 (95% CI: 0.93–0.96), 0.80 (95% CI: 0.76–0.84), 0.71 (95% 
CI: 0.68–0.73) and 0.56 (95% CI, 0.48–0.63) respectively. 
The 1-year survival rate in a 2009 study from England 
(96%) and Australia (98.1%) is consistent with the results 
of our study (13). The 1- and 3-year survival rates were 
reported in a 2014 study from China as 76.0–83.1% and 
51.5–74.1%, respectively (14). In a 2004 study conducted in 
India, the 1- and 3-year survival rates were 76% and 51.5% 
respectively (15). Our findings indicate that the 1-year 
survival rates in the EMR are similar to those in some 
developed countries and better than in some developing 
countries such as India.
In a 2015–2016 report from the American Cancer 
Society the 5- and 10-year relative survival rates were 
89% and 83% respectively (16). In a study conducted in 
European countries in 2013, the 5-year relative survival 
rate was 69–84% (17). On the other hand, in a 2010 study 
conducted in developing countries, the 5-year relative 
survival rate varied from 52% in India to 82% in China 
(18). Comparing with our findings, the 5- and 10-year 
survival rates in the EMR were lower than in the high-
income countries and similar to those in the developing 
countries.
An important factor that may account for the 
differences in survival rates among women with breast 
cancer in the EMR might be the (lack of) improvement of 
the health systems in some countries; a poorly developed 
health system can result in late diagnosis and improper 
treatment of patients with advanced cancer. Additionally, 
the lack of a population-based cancer registry in some 
countries may result in insufficient surveillance and 
a failure in monitoring any control programme. False 
beliefs and low levels of knowledge and awareness in 
some populations in the Region are other likely reasons 
for these differences (1,5,19). Survival data in the EMR 
depend on good registries. Some countries do have data, 
some have data but the quality is not known, and some 
1165 records identified through  
database searching
127 additional records identified  
through other sources
328 records after duplicates 
removed
964 records screened 
93 full-text articles assessed 
for eligibility
80 studies included in 
qualitative synthesis
80 studies included in 
quantitative synthesis 
(meta-analysis)  
871 records excluded 
13 full-text articles excluded, 
with reasons
Figure 1 PRISMA flow diagram showing the different phases involved in the search process
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Table 2 Subgroup analysis for 1-, 3-, 5- and 10-year survival rates of women with breast cancer in the Eastern Mediterranean 
Region (EMR), 1946–2018
Category/ subgroup Survival rate (95% confidence interval)
1-year 3-year 5-year 10-year
Sex
Female 0.95 (0.93–0.96) 0.80 (0.76–0.84) 0.71 (0.68–0.73) 0.56 (0.48–0.63)
Male – 0.84 (0.75–0.92) 0.63 (0.59–0.67) 0.41 (0.25–0.59)
Decade of study
1990–1999 0.93 (0.92–0.94) 0.76 (0.71–0.80) 0.63 (0.58–0.68) 0.50 (0.45–0.55)
2000–2009 0.96 (0.93–0.98) 0.84 (0.77–0.89) 0.72 (0.68–0.75) 0.58 (0.47–0.69)
2010–2018 0.95 (0.91–0.97) 0.77 (0.70–0.84) 0.72 (0.67–0.76) 0.56 (0.42–0.69)
Stage at diagnosis
I – – 0.90 (0.81–0.97) –
II – – 0.77 (0.71–0.83) –
III – – 0.57 (0.49–0.64) –
IV – – 0.37 (0.19–0.57) –
Age (years)
Under 39 – – 0.74 (0.68–0.80) –
40–64 – – 0.76 (0.66–0.85) –
65+ – – 0.58 (0.46–0.69) –
Ethnicity
Arab 0.93 (0.88–0.97) 0.83 (0.75–0.90) 0.69 (0.62–0.75) 0.51 (0.42–0.60)
Other 0.95 (0.94–0.97) 0.78 (0.74–0.82) 0.71 (0.69–0.74) 0.57 (0.47–0.66)
Human Development Index
Very high 0.91 (0.83–0.97) 0.81 (0.78–0.83) 0.68 (0.60–0.75) 0.48 (0.40–0.56)
High 0.95 (0.94–0.97) 0.78 (0.74–0.82) 0.69 (0.66–0.72) 0.59 (0.48–0.71)
Medium 0.97 (0.95–0.98) 0.89 (0.80–0.96) 0.82 (0.73–0.90) –
Low – – 0.73 (0.64–0.80) 0.54 (0.35–0.73)
EMR country groupinga
Group 1 0.91 (0.83–0.97) 0.80 (0.77–0.82) 0.70 (0.64–0.75) 0.48 (0.40–0.56)
Group 2 0.96 (0.94–0.97) 0.78 (0.73–0.83) 0.68 (0.66–0.71) 0.54 (0.44–0.64)
Group 3 – – 0.67 (0.57–0.77) 0.58 (0.43–0.72)
aAll 22 countries in the Region are categorized into 3 groups based on level of development and income. Group 1: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates. Group 
2: Egypt, Islamic Republic of Iran, Iraq, Jordan, Lebanon, Libya, Morocco, occupied Palestinian territory, Syrian Arab Republic and Tunisia. Group 3: Afghanistan, Djibouti, Pakistan, Somalia, 
Sudan and Yemen.
low-income countries have no published papers on 
survival. Consequently, our results actually represent 
the pooled survival rates of patients with breast cancer 
in those countries in the EMR which have better health 
care systems.
The results of the subgroup analysis indicated that 
women with breast cancer who were younger than 39 
years may have the lowest survival rate. The highest 
survival rate was in those aged 40–64 years. In a study 
from Sweden in 2009 the 5-year survival rates in women 
aged 20–34, 35–39, 40–49 and 50–69 years were 74.7%, 
83.8%, 88.3% and 87.8% respectively (20), which was 
consistent with the result of our study. Also, the results 
from a 2016 study in Canada (21) and a 2017 Iranian study 
(22) confirm our findings. Some research has reported 
that the age of onset of breast cancer in women of the 
EMR and also Asian women is lower than their European 
and American counterpart (23). Breast cancer is a rare 
disease in young women, however the clinical and 
pathological outcomes are more aggressive than in older 
patients (20,21). Several studies have indicated that age is 
a significant predictor of survival in patients with breast 
cancer. A number of factors may affect the survival rates 
in women with breast cancer, e.g. late presentation and 
diagnosis at an advanced stage, more aggressive tumours 
in young women (20,24,25), and hormonal, immunological 
and biological differences between younger and older 
women (26,27). This hormonal difference in young 
women may result in more rapidly growing tumour and 
thus reduced survival rates (26,28). Also younger women 
with breast cancer may have more recurrence than other 
age groups (26). 
One of the most important prognostic factors 
for survival of patients with breast cancer is stage at 
226
EMHJ – Vol. 26 No. 2 – 2020Review
Table 3 Meta-regression analysis for assessing the effect of suspected variables on the pooled 1-, 3-, 5- and 10-year’s survival rate 
for women with breast cancer in the Eastern Mediterranean Region, 1946–2018
Survival Variable Univariable model Multivariable model
β SE P-value β SE P-value
1-year Sample size 2.7 2.4 0.281 –0.7 2.3 0.761
HDI 3.1 4.8 0.525 11.8 5.2 0.032
Decade of study 3.1 3.0 0.763 –5.9 3.2 0.091
Ethnicity 4.4 2.2 0.068 9.7 3.1 0.007
3-year Sample size –1.9 4.6 0.612 –1.3 4.3 0.752
HDI 11.8 4.8 0.028 11.0 7.5 0.134
Decade of study 4.0 5.0 0.482 1.5 6.0 0.823
Ethnicity –4.2 4.1 0.329 –0.6 5.9 0.914
5-year Sample size 3.6 3.1 0.234 3.0 2.9 0.325
HDI 9.0 3.6 0.012 8.1 3.7 0.036
Decade of study 8.2 3.9 0.048 5.4 4.1 0.179
Ethnicity 2.9 3.0 0.397 2.2 9.9 0.425
10-year Sample size –2.7 9.2 0.752 –0.6 11.0 0.981
HDI –1.0 10.3 0.952 –3.0 11.0 0.834
Decade of study 10.5 12.1 0.443 11.0 20.0 0.516
Ethnicity 5.5 9.6 0.526 –0.3 37.7 0.327
SE = standard error.
HDI = Human Development Index.
diagnosis. The result of our study indicated that the 
5-year survival rate of women with breast cancer in the 
EMR ranged from 90% for stage I to 37% for stage IV. In a 
2016 report from the American Cancer Society the 5-year 
relative survival rate was between 99% at the local stage 
and 26% at the distant stage (16), similar to our findings. 
Also, a study from India in 2004 reported that the 5-year 
survival rate was from 69.7% at the local stage to 4% at 
the distant metastasised stage (15), which was much 
lower than our finding in the EMR. In developing region 
like the EMR, patients with breast cancer are usually 
diagnosed at an advanced stage due to the limited health 
care facilities, lack of awareness, and social barriers and 
cultural beliefs that can result in reduced survival (2). 
Our findings indicated that the survival rate for 
women of all ages with breast cancer was better in the 
most recent decade. The 5-year survival rate in women 
in the EMR increased from 63% in 1990–1999 to 72% in 
2010–2018. The result of studies conducted in Canada (29) 
and in England (13) confirm our findings. This progress 
may be due to the screening programmes and cancer 
prevention and control strategies in the countries of the 
Region (1,30). 
The survival rate of women with breast cancer in 
the Arab populations was lower than in the non-Arab 
populations in this Region. In a 2016 meta-analysis 
conducted in the Islamic Republic of Iran, the pooled 1-, 
3-, 5- and 10-year survival rates in women were 95%, 80%, 
69% and 55% respectively (31) and in a study from Jordan 
in 2010 the 1-, 3- and 5-year survival rates were 91%, 70% 
and 59% respectively (32), confirming the result of our 
study. The results of some studies indicate that Arab 
women with breast cancer may have a worse prognosis 
than other populations (33,34). The reasons for this may 
be the young age of women at presentation and also late 
diagnosis (34). Also some studies noted that the proportion 
of negative estrogen and progesterone receptors in Arab 
women with breast cancer was high, which can lead to 
poor survival (33,35,36). 
In our meta-analysis we found that the 5-year survival 
rate in women was better than in men. Several studies 
indicate that sex is not an independent significant 
predictor for breast cancer survival (37–39) and the 
differences in survival may be due to the similarity 
between breast cancer in men and postmenopausal 
breast cancer in women (37,40). Some studies note that 
male breast cancer was diagnosed approximately 5–10 
years later than in women (41,42). Also because of the 
general dearth of breast cancer screening programmes 
foe males, they are usually diagnosed at a later stage 
than women (42,43). In some studies, the risk of local 
and regional recurrence in male breast cancer has been 
higher than women (42,44). 
We found that the 5-year survival rate in the very 
high HDI subgroup was much lower than in the low 
HDI subgroup. In the medium and low HDI subgroups 
we have countries such as Afghanistan, Djibouti, Iraq, 
Palestine, Sudan, Somalia and Syrian Arab Republic but 
we did not have any relevant study about the survival 
rate for breast cancer in these countries, so the pooled 
survival rate in these subgroups are concluded from only 
a few countries, and therefore we should expect this bias.
One of the main limitations of this review is that, from 
the 22 countries in the EMR, we only have studies from 
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12 countries. So the estimate of the pooled survival rate 
in this Region can be representative of survival of only 
those countries which have a better health care system. 
Conclusion
Although the search targeted all EMR countries, our re-
sults represented countries in the EMR with better health 
care systems, because the countries with no published 
papers on survival are mainly low income countries. 
The survival rate of women in the countries in the EMR 
which have better health care systems is between the 
rates in the developed and developing regions. We found 
that, as in other parts of the world, survival rate have im-
proved in recent decades. Although the survival rate will 
further improve owing to the implementation of screen-
ing and control programmes, we need more informative 
programmes to improve the awareness among females 
about the early sign and symptoms of this disease. 
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Taux de survie des patients atteints de cancer du sein dans les pays de la Région de la 
Méditerranée orientale : analyse systématique et méta-analyse
Résumé
Contexte : Le cancer du sein est la quatrième cause de mortalité et d’incapacité dans la Région de la Méditerranée 
orientale  ; bien que son incidence soit moindre que dans les régions développées, la tendance a été à la hausse au cours 
des dernières décennies.
Objectif : La présente étude avait pour objectif de calculer le taux de survie combiné des patients atteints de cancer du 
sein dans la Région de la Méditerranée orientale. 
Méthodes : Nous avons effectué des recherches dans les bases de données électroniques de 1946 au 19 janvier 2018, 
sans restriction de langue. Un modèle à effet aléatoire a été utilisé pour estimer les taux de survie combinés à 1, 3, 5 et 
10 ans pour les patients atteints de cancer du sein. Le test χ² et l’indice I2 ont été utilisés pour évaluer l’hétérogénéité 
entre les études. Une analyse de sous-groupe et une méta-régression ont été utilisées pour étudier la source potentielle 
d’hétérogénéité. 
Résultats : Nous avons trouvé 80 articles éligibles pour être inclus dans notre analyse. Les taux de survie combinés à 1, 3, 
5 et 10 ans chez les femmes atteintes de cancer du sein dans la Région de la Méditerranée orientale étaient respectivement 
de 0,95 ; 0,80 ; 0,71 et 0,56. L’indice I2 a mis en évidence une hétérogénéité considérable entre les études (toutes ayant 
rapporté un indice I2 supérieur à 50 %). Le taux de survie à 5 ans dans le sous-groupe masculin était de 0,63. Le taux de 
survie à 5 ans chez les femmes atteintes de cancer du sein dans les tranches d’âge inférieur ou égal à 39, compris entre 40 
et 64 ans et des plus de 65 ans étaient respectivement de 0,74 ; 0,76 et 0,58. Une corrélation statistiquement significative 
a été relevée entre l’indice de développement humain (β = 9, p = 0,01), la décennie de l’étude (β = 8,2, p = 0,04) et le taux 
de survie à 5 ans. 
Conclusions : Le taux de survie des femmes atteintes de cancer du sein dans les pays de la Région de la Méditerranée 
orientale qui ont les meilleurs systèmes de santé s’est amélioré au cours de la dernière décennie. Les femmes dont l’âge 
était compris entre 40 et 64 ans avaient le meilleur taux de survie.
معدالت نجاة املرىض املصابني برسطان الثدي يف إقليم رشق املتوسط: استعراض منهجي وحتليل تلوي
خدجية ماجاين، حممود خودادوست، آرش فتاحي، عليار بريوزي
اخلالصة
اخللفية: رسطان الثدي هو رابع سبب رئييس للوفاة والعجز يف إقليم رشق املتوسط؛ وأصبح هناك اجتاه متزايد لإلصابة برسطان الثدي، عىل الرغم 
من أن معدل اإلصابة به ال يزال أقل من املعدالت السائدة يف األقاليم املتقدمة.
عة للمرىض املصابني برسطان الثدي يف إقليم رشق املتوسط.  األهداف: متثََّل هدفنا يف حساب معدل النجاة امُلجمَّ
طرق البحث: بحثنا يف قواعد البيانات اإللكرتونية يف الفرتة من عام 1946 إىل 19 يناير/كانون الثاين 2018، بدون أي قيود لغوية. وقد استخدمنا 
عة عىل مدار سنة واحدة، و3 سنوات، و5 سنوات و10 سنوات للمرىض املصابني برسطان  نموذجًا عشوائيًا فعااًل لتقدير معدالت النجاة امُلجمَّ
ي املصدر  ف التلوي لتحرِّ الثدي. واسُتخدم اختبار χ2 ومؤرش I2 لتقييم التباين بني الدراسات. كذلك اسُتخدم حتليل املجموعات الفرعية والتحوُّ
امُلحتمل للتباين.
عة عىل مدار سنة واحدة، و3 سنوات، و5 سنوات  النتائج: وجدنا أن هناك 80 مقااًل صاحلًا لإلدراج ضمن املراجعة. وبلغت معدالت النجاة امُلجمَّ
و10 سنوات بني النساء املصابات برسطان الثدي يف إقليم رشق املتوسط 0.95، و0.80، و0.71، و0.56 عىل التوايل. وبنيَّ مؤرش I2 وجود 
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